by Madaline Spencer | Dec 10, 2024
Bruce Leuchter, MD, CEO of Neurvati Neurosciences and GRIN Therapeutics, discusses the initiation of the Astroscape clinical trial for tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) type II. TSC is characterized by the growth of...
by Madaline Spencer | Dec 9, 2024
Obi Umeh, MD, VP, Franchise Global Program Leader at Takeda, discusses positive interim results from study of mezagitamab for IgA nephropathy. IgA nephropathy is a kidney disorder that occurs when IgA accumulates in the kidneys. In the early stages,...
by Madaline Spencer | Dec 6, 2024
Darcy Trimpe, PhD, U.S. Medical Director at Amgen, discusses real world data on Tavneos (avacopan) for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). GPA is a type of vasculitis of the blood vessels. The disease can...
by Madaline Spencer | Dec 5, 2024
Carla Nester, MD, University of Iowa Stead Family Children’s Hospital, discusses results from the clinical trial of iptacopan in complement 3 glomerulopathy (C3G). C3G is a rare kidney disease characterized by damage to kidney glomeruli due to abnormal...
by Madaline Spencer | Dec 4, 2024
Jack Johnson, Co-Founder and Executive Director of the Fabry Disease Support and Information Group, and VP of the Fabry International Network, discusses the phase 3 BRIGHT study testing Elfabrio (pegunigalsidase alfa-iwx) in patients with Fabry disease. ...
